Clinical trial
Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed…
NCT00452569 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00452569 |
|---|---|
| Title | Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma |
| Official title | Randomised, Controlled, Open-labelled, Multi-centre Comparison of Thalidomide Versus High-dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma |
| Acronym | OPTIMUM |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Thalidomide, Dexamethasone |
| Enrollment | 499 |
| Start date | Feb 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Mar 27, 2007 |
| Last update posted | Nov 18, 2019 |
| Countries | Bulgaria, Croatia, Czechia, France, Germany, Hungary, India, Italy, Philippines, Poland, Portugal, Serbia and 3 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: